openPR Logo
Press release

Creative Biolabs Accelerates Antisense Oligonucleotide Innovation Amid Breakthroughs in RNA-Based Therapies

08-21-2025 04:00 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Getnews

/ PR Agency: PRChoices
Creative Biolabs Accelerates Antisense Oligonucleotide

Accelerating the development of antisense oligonucleotide (ASO) therapy through Creative Biolabs' end-to-end ASO design, synthesis, and conjugation solutions.
New York, USA - August 21, 2025 - A seminal paper in Nature Chemistry last month showed how designed ASOs are capable of dismantling disease-causing toxic RNA clumps for conditions like ALS and Huntington's. It's a paradigm shift. They discovered how these RNA clumps form and demonstrated that ASOs can reverse them-opening a new frontier in neurotherapeutics.

Image: https://www.getnews.info/uploads/0c59d26f78bf6dd58aafee5bc68d7d8c.jpg

In a year of revolutionary discoveries in RNA biology, it is the privilege of Creative Biolabs to reassert its leadership in the development of antisense oligonucleotide (ASO) therapy through its end-to-end, one-stop-shop ASO design [https://www.creative-biolabs.com/gene-therapy/aso-design-synthesis.htm], synthesis, and conjugation solutions. With recent research casting further insight into the therapeutic potential of ASOs to treat neurodegenerative and orphan genetic diseases, Creative Biolabs takes center stage, enabling researchers and biotechs to accelerate breakthroughs in research.

Creative Biolabs' ASO platform is capable of tackling this frontier. Their one-stop ASO development [https://www.creative-biolabs.com/gene-therapy/one-stop-antisense-oligonucleotide-aso-development.htm] service places the entire process-target gene analysis and sequence design, chemical modification to delivery optimization-in one stop. The customers get a seamless workflow wherein overhead is reduced, timelines are compressed, and technical accuracy is optimized.

"We're committed to making innovation possible," a scientist at Creative Biolabs asserted. "Whether you're searching for a low-abundance mutation or designing a successful therapy, our ASO technologies are ready to serve. We've brought together next-gen algorithms, proprietary screening models, and delivery technologies to meet the evolving demands of RNA medicine."

These ASO design & synthesis products of the company consist of first- and second-generation chemistries such as phosphorothioate backbones and 2'-O-methoxyethyl modifications and gapmer structures to provide improved RNase H activity. These modifications provide stability, reduce immunogenicity, and improve target specificity-all cornerstones of clinical success.

Moreover, Creative Biolabs offers ASO conjugate development [https://www.creative-biolabs.com/gene-therapy/aso-conjugate-development.htm], with delivery systems including GalNAc conjugates to target the liver, peptide and aptamer conjugates to target tissue, and lipid nanoparticles (LNPs) for systemic targeting. These platforms are essential in overcoming the pharmacokinetic barrier of ASO therapeutics.

"Creative Biolabs was a huge help in assisting us to optimize our ASO candidates," a director with a biotech start-up focused on rare disease drugs said. "Their technical know-how and quick turnaround provided us with the comfort level to move forward with our IND filing."

As the ASO market keeps expanding-into individualized therapies for ultra-rare diseases and massive therapies for Alzheimer's and cancer-Creative Biolabs is dedicated to making scientific progress simpler.

Learn more, please visit https://www.creative-biolabs.com/gene-therapy.

About Creative Biolabs

Creative Biolabs is a globally renowned biotech company specializing in novel drug discovery and gene therapy technology. It is a market leader in the nucleic acid therapeutic industry that has become a trusted name as a collaborator with scientists and pharma developers requiring novel technologies in antisense oligonucleotides (ASOs), mRNA medicine, and CRISPR-based platforms.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email [http://www.universalpressrelease.com/?pr=creative-biolabs-accelerates-antisense-oligonucleotide-innovation-amid-breakthroughs-in-rnabased-therapies]
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/gene-therapy

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Creative Biolabs Accelerates Antisense Oligonucleotide Innovation Amid Breakthroughs in RNA-Based Therapies here

News-ID: 4154701 • Views:

More Releases from Getnews

Inverted Leadership - Growing Empowered Teams from the Ground Up
Inverted Leadership - Growing Empowered Teams from the Ground Up
Image: https://www.globalnewslines.com/uploads/2025/08/1755782349.jpg This season, if you are determined to adopt a growth-oriented, healthy and nature-inspired framework, then you need to get your hands on Richard J. Haley's [https://www.amazon.com/dp/1968615431] business leadership book, Inverted Leadership. It is a deeply insightful guide that asks leaders to stop looking down on their teams and start building up from them. In a world where command-and-control management is obsolete, Haley invites us to embrace an entirely new
Adelante Community Development Founder and CEO Maria Gonzalez Named One of Colorado's Top 25 Most Powerful Women in Business
Adelante Community Development Founder and CEO Maria Gonzalez Named One of Color …
Image: https://www.globalnewslines.com/uploads/2025/08/73ad26940c9117baf905054241e3f4ae.jpg Commerce City, CO - The Colorado Women's Chamber of Commerce (CWCC) has recognized Maria Gonzalez, Founder and CEO of Adelante Community Development, as one of the 2025 Top 25 Most Powerful Women in Business. This prestigious honor highlights Maria's visionary leadership, her dedication to advancing Latino entrepreneurs, and her impact on shaping Colorado's economic landscape. The CWCC Top 25 Most Powerful Women in Business award celebrates leaders who excel in
Commercial Refrigeration Repair Denver Now Offered by Climate Alignment Refrigeration, Heating & Air Conditioning
Commercial Refrigeration Repair Denver Now Offered by Climate Alignment Refriger …
Image: https://www.globalnewslines.com/uploads/2025/05/1746205444.jpg Climate Alignment Refrigeration, Heating & Air Conditioning has expanded its services to offer all-inclusive commercial refrigeration repair in Denver, providing businesses with reliable solutions for their cooling and freezing equipment needs. Climate Alignment Refrigeration, Heating & Air Conditioning [https://climatealignmenthvacr.com/] has expanded its services to offer all-inclusive commercial refrigeration repair in Denver, providing businesses with reliable solutions for their cooling and freezing equipment needs. "Our expanded commercial refrigeration repair services reflect
Air Voel Expands Inventory with Advanced BiPAP Machines for Complex Sleep Apnea Cases
Air Voel Expands Inventory with Advanced BiPAP Machines for Complex Sleep Apnea …
Air Voel, Canada's trusted source for CPAP and sleep therapy devices, announced today that it has expanded its product inventory to now include advanced BiPAP machines designed specifically for patients with more complex sleep apnea cases. This expansion reflects Air Voel's commitment to meeting the growing needs of Canadians who require more specialized respiratory support beyond standard CPAP therapy. Understanding the Need for BiPAP Therapy While CPAP machines are considered the gold

All 5 Releases


More Releases for ASO

Global Assortment And Space Optimization (ASO) Market Analysis 2025-2030: Growth …
The Assortment And Space Optimization (ASO) Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. How Big Is the Assortment And Space Optimization (ASO) Market Size Expected to Be by 2034? The market size of the assortment and space optimization (ASO) sector has seen significant expansion in
Antisense Oligonucleotide Drugs(ASO Drugs) Market Key Players, Share and Forecas …
" The global antisense oligonucleotide (ASO) drugs market is poised for significant growth, with a projected market value of approximately $4.9 billion in 2024. The market is anticipated to expand to around $11.5 billion by 2034, reflecting a compound annual growth rate (CAGR) of about 8.7% during the forecast period from 2025 to 2034. " Exactitude Consultancy., Ltd. released a research report titled "Antisense Oligonucleotide Drugs(ASO Drugs) Market". This report covers
Antisense Oligonucleotides (ASO) Drug Market is estimated to reach USD 12.3 bill …
" The global Antisense Oligonucleotides (ASO) drug market is projected to reach approximately $5.8 billion in 2024, driven by increasing applications in molecular therapeutics and genetic disorders. The market is expected to expand significantly, with a forecasted value of around $12.3 billion by 2034, reflecting robust demand and technological advancements in oligonucleotide therapeutics." Exactitude Consultancy., Ltd. released a research report titled "Antisense Oligonucleotides (ASO) Drug Market". This report covers the global
Antisense Oligonucleotide (ASO) Therapeutics Market Size to Reach USD 7,864.9 Mi …
The Antisense Oligonucleotide (ASO) Therapeutics market, valued at USD 2,355.4 million in 2024, is expected to register robust revenue CAGR of 16.2%. Request free copy of this report: https://navistratanalytics.com/request-free-sample/1256 June 02, 2025 - The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense Oligonucleotide (ASO) therapeutics market. For instance, the American Lung Association reports that cystic fibrosis affects approximately 40,000 individuals in the
Assortment and Space Optimization (ASO) Market Sets the Table for Continued Grow …
A Latest intelligence report published by Market Research Forecast with title "Global Assortment and Space Optimization (ASO) Market Outlook to 2032. A detailed study accumulated to offer Latest insights about acute features of the Assortment and Space Optimization (ASO) market. This report provides a detailed overview of key factors in the Global Assortment and Space Optimization (ASO) Market and factors such as driver, restraint, past and current trends, regulatory scenarios
FDA Releases Draft Guidance on CMC For Individualized ASO Therapies
SAE Media Group proudly presents the return of the Oligonucleotide Therapeutics & Delivery Conference on the 21st and 22nd September 2022 in London, UK. The two-day conference will bring you high-quality insights and industry connections on the latest clinical trial candidates and a platform for exchanging ideas for tackling the biggest challenge: DELIVERY. Personalized medicine continues to be at the cutting edge of healthcare, pharmaceuticals, and biotechnology. For patients afflicted with